A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Japanese Subjects With Palmoplantar Pustulosis

PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

October 16, 2019

Primary Completion Date

January 18, 2021

Study Completion Date

June 7, 2021

Conditions
Palmoplantaris Pustulosis
Interventions
DRUG

Apremilast

Apremilast

DRUG

Placebo

Placebo

Trial Locations (22)

491-8558

Research Site, Ichinomiya

467-8602

Research Site, Nagoya

814-0180

Research Site, Fukuoka

060-0063

Research Site, Sapporo

317-0077

Research Site, Hitachi

252-0392

Research Site, Sagamihara-shi

221-0825

Research Site, Yokohoma-shi

238-8558

Research Site, Yokosuka

693-8501

Research Site, Izumo

102-8798

Research Site, Chiyoda-ku

173-8606

Research Site, Itabashi-ku

173-8610

Research Site, Itabashi-ku

292-8535

Research Site, Kisarazu

400-0027

Research Site, Kofu

505-8503

Research Site, Minokamo

783-8505

Research Site, Nankoku-shi

550-0006

Research Site, Osaka

980-8574

Research Site, Sendai

161-8521

Research Site, Shinjuku-ku

160-0023

Research Site, Shinjyuku-ku

791-0295

Research Site, Tōon

514-8507

Research Site, Tsu

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY